Requirements for Parkinson’s disease pharmacotherapy from the patients’ perspective: a questionnaire-based survey
| Autor: | Jan Kassubek, G. Fuchs, Olaf Randerath, Ullrich Wüllner, Nicole Reketat |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Levodopa Parkinson's disease MEDLINE adverse effects [Levodopa] therapeutic use [Levodopa] Disease Antiparkinson Agents Questionnaire based survey Pharmacotherapy Quality of life Surveys and Questionnaires adverse effects [Antiparkinson Agents] medicine Humans ddc:610 therapeutic use [Antiparkinson Agents] Aged Aged 80 and over business.industry Perspective (graphical) Parkinson Disease General Medicine Middle Aged medicine.disease drug therapy [Parkinson Disease] Treatment Outcome Quality of Life Physical therapy Female business medicine.drug |
| Zdroj: | Current medical research and opinion 28(7), 1239-1246 (2012). doi:10.1185/03007995.2012.702101 |
| ISSN: | 1473-4877 0300-7995 |
| Popis: | Knowledge of patients' treatment needs is an important requirement for comprehensive long-term patient care. The objective of this investigation was to assess the requirements of patients with Parkinson's disease (PD) regarding pharmacotherapy.A total of 17,500 members of the German Parkinson Association were given the opportunity to anonymously answer a questionnaire about their health-related quality of life, PD pharmacotherapy and their improvement suggestions for new PD medication.Answers from 6351 patients were available for analysis. The majority (87.2%) of patients were older than 60 years; 88.9% had been diagnosed with PD for longer than 3 years and 84.4% selected one of the three most severe categories (categories 1-3 on a 6-point scale) when rating the impact of PD on their quality of life. Symptoms that were regarded as very important for improvement with pharmacotherapy included motor fluctuations (66.3%), early morning akinesia (55.4%) and sleep disturbances (43.5%). Properties of a new PD medication that were rated as very important included continuous drug delivery over 24 hours (66.6%) and 24-hour symptom control (55.8%). The majority of patients used physicians (84.2%) and/or self-help groups (69.4%) to obtain information about PD. Topics of particular interest included comorbid diseases (78.3%), mobility and exercise (77.3%) and research (53%).PD has a major impact on patients' quality of life. From the patient's perspective, PD pharmacotherapy needs to address a range of symptoms including not only motor symptoms, but also non-motor symptoms such as sleep disturbances. In selecting the most appropriate treatment regimen, patient preference is an important consideration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|